Related Experiment Video
Updated: Jul 12, 2026
Cardiopulmonary Bypass in a Mouse Model: A Novel Approach
Published on: September 22, 2017
Effects of In-House Cryoprecipitate Use on Transfusion Volume for Cardiopulmonary Bypass Surgery
Wakana Niwa1, Yoshiyuki Takami1, Atsuo Maekawa1
1Department of Cardiac Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Purpose:
Cryoprecipitate has been covered by Japanese national health insurance since 2020 for cardiopulmonary bypass (CPB)-induced hypofibrinogenemia. This study evaluated the clinical efficacy of in-house cryoprecipitate use in patients undergoing CPB.
Methods:
A total of 1357 patients were divided into 2 groups before and after cryoprecipitate introduction in February 2020 (Group A, n = 685; Group B, n = 672). Propensity score matching also compared 205 pairs between transfused patients in Group A (Group A', n = 597) and those receiving cryoprecipitate in Group B (Group B', n = 222).
Results:
Cryoprecipitate was used in 222 patients (37%) in Group B. While overall transfusion rates did not differ significantly, postoperative red blood cell (20% vs 13%, p <0.01) and platelet concentrate (PC) (35% vs 12%, p <0.01) use were significantly lower in Group B. In the matched cohorts, including ~70% undergoing aortic surgery, postoperative PC use was significantly reduced in Group B' (26% vs 18%, p = 0.04).
Conclusions:
In-house cryoprecipitate use was associated with reduced postoperative PC transfusion, particularly in aortic surgery involving prolonged CPB and deep hypothermic circulatory arrest. A cryoprecipitate-centered hemostatic strategy, supplementing multiple coagulation factors beyond fibrinogen, may be effective in complex CPB procedures.
